Earlier this week Spanish business publication Intereconomia suggested that either Roche or Amgen could be interested in Alexion, which has just unveiled its results. However, some sources have suggested that the timeframe on anything happening here could be rather more immediate than the few months initially implied – perhaps even as soon as in days.
That said, so far shares of Alexion appear to be content to test for support, even though, firstly its rare diseases space is one of strong growth, and after offering an impressive update on its Soliris treatment today. Presumably, now that the results are out of the way any would be bidder has the road clear to act if they so wish.
Zakmir.com is a purely journalistic website – Zak Mir is a member of the National Union of Journalists. There is no intention here of providing financial advice. It is recommended you seek an independent professional opinion before deciding whether or not to take any action with regard to anything written here.